{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:59Z","timestamp":1786982519883,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR-T)-mediated therapies have shown promising clinical benefit in patients with refractory or relapsing (R\/R) diffuse large B-cell lymphoma (DLBCL). However, CAR-T treatment presents challenges such as lack of drug accessibility, financial barriers, variable physician preference or experience, and risk assessment based on patient-specific characteristics. This article thus aims to provide an overview of the CAR-T landscape for R\/R DLBCL in Asia, with a focus on identifying barriers to access, from the perspective of Asian and international lymphoma experts. Presently, existing clinical data indicate that CAR-T therapy is a potentially curative strategy for R\/R DLBCL in addition to stem cell transplantation, provided the patient\u2019s disease profile and treatment history have been thoroughly considered. However, longer-term follow-up data from large-scale studies are needed to confirm curative potential and define optimal sequencing of CAR-T in the context of novel emerging treatments, such as bi-specific antibodies, in the management of R\/R DLBCL. Consequently, further research into CAR-T would benefit from collaboration between institutions. Furthermore, there is a wide disparity in CAR-T accessibility across regions due to complicated logistics and cost, which represent a significant barrier to patients in Asia. Hence, there is a need to increase representation and engagement across different stakeholders such as policymakers, payers, and the industry to arrive at a consensus on patient selection, establish clear guidelines, and develop strategies to lower CAR-T costs. Ultimately, data can support a multi-stakeholder approach when devising strategies to make CAR-T feasible and sustainable for patients.<\/jats:p>","DOI":"10.1007\/s12672-025-01860-5","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T23:59:58Z","timestamp":1739491198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia"],"prefix":"10.1007","volume":"16","author":[{"given":"Ya Hwee","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Liang","family":"Boo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagavalli","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Yeu","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Jeyasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Yongsheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"1860_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00754-8","author":"JY Chan","year":"2023","unstructured":"Chan JY, Somasundaram N, Grigoropoulos N, Lim F, Poon ML, Jeyasekharan A, et al. Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations. Discov Oncol. 2023. https:\/\/doi.org\/10.1007\/s12672-023-00754-8.","journal-title":"Discov Oncol"},{"key":"1860_CR2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.11.006","author":"LK Hilton","year":"2023","unstructured":"Hilton LK, Scott DW, Morin RD. Biological heterogeneity in diffuse large B-cell lymphoma. Seminars Hematol. 2023. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.11.006.","journal-title":"Seminars Hematol"},{"key":"1860_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.003","author":"MS Hoffmann","year":"2023","unstructured":"Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming barriers to referral for chimeric antigen receptor t cell therapy in patients with relapsed\/refractory diffuse large b cell lymphoma. Transplant Cell Ther. 2023. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.003.","journal-title":"Transplant Cell Ther"},{"key":"1860_CR4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"Cancer J Clin"},{"key":"1860_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-019-01155-5","author":"A Miranda-Filho","year":"2019","unstructured":"Miranda-Filho A, Pi\u00f1eros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019. https:\/\/doi.org\/10.1007\/s10552-019-01155-5.","journal-title":"Cancer Causes Control"},{"key":"1860_CR6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158830","author":"E Sedeta","year":"2022","unstructured":"Sedeta E, Ilerhunmwuwa N, Wasifuddin M, Uche I, Hakobyan N, Perry J, et al. Epidemiology of non-hodgkin lymphoma: global patterns of incidence, mortality, and trends. Blood. 2022. https:\/\/doi.org\/10.1182\/blood-2022-158830.","journal-title":"Blood"},{"key":"1860_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1059914","author":"Y Chu","year":"2023","unstructured":"Chu Y, Liu Y, Fang X, Jiang Y, Ding M, Ge X, et al. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1059914.","journal-title":"Front Oncol"},{"key":"1860_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29635","author":"RBT Lim","year":"2015","unstructured":"Lim RBT, Loy EY, Lim GH, Zheng H, Chow KY, Lim ST. Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012. Int J Cancer Res. 2015. https:\/\/doi.org\/10.1002\/ijc.29635.","journal-title":"Int J Cancer Res"},{"key":"1860_CR9","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.089","author":"JS Kim","year":"2020","unstructured":"Kim JS, Liu Y, Ha KH, Qiu H, Rothwell LA, Kim HC. Increasing incidence of b-cell non-Hodgkin lymphoma and occurrence of second primary malignancies in south Korea: 10-year follow-up using the Korean national health information database. Cancer Res Treat. 2020. https:\/\/doi.org\/10.4143\/crt.2020.089.","journal-title":"Cancer Res Treat"},{"key":"1860_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15926","author":"Y Usui","year":"2023","unstructured":"Usui Y, Ito H, Katanoda K, Matsuda T, Maeda Y, Matsuo K. Trends in non-Hodgkin lymphoma mortality rate in Japan and the United States: a population-based study. Cancer Sci. 2023. https:\/\/doi.org\/10.1111\/cas.15926.","journal-title":"Cancer Sci"},{"key":"1860_CR11","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204006","author":"W Liu","year":"2022","unstructured":"Liu W, Liu J, Song Y, Wang X, Mi L, Cai C, et al. Burden of lymphoma in China, 1990\u20132019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging. 2022. https:\/\/doi.org\/10.18632\/aging.204006.","journal-title":"Aging"},{"key":"1860_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0.","journal-title":"Lancet"},{"key":"1860_CR13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2023020854.","journal-title":"Blood"},{"key":"1860_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ. Five-year outcomes for refractory b-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMc2030164.","journal-title":"N Engl J Med"},{"key":"1860_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00662-6","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6.","journal-title":"Lancet"},{"key":"1860_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30864-7","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019. https:\/\/doi.org\/10.1016\/s1470-2045(18)30864-7.","journal-title":"Lancet Oncol"},{"key":"1860_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large b-cell lymphoma. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"key":"1860_CR18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large\u00a0B-cell lymphoma. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022018893.","journal-title":"Blood"},{"key":"1860_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"1860_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"key":"1860_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00375-2","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021. https:\/\/doi.org\/10.1016\/s1470-2045(21)00375-2.","journal-title":"Lancet Oncol"},{"key":"1860_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large b-cell lymphoma. N Engl J Med. 2023. https:\/\/doi.org\/10.1056\/NEJMoa2301665.","journal-title":"N Engl J Med"},{"key":"1860_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00428-w","author":"A Gajra","year":"2022","unstructured":"Gajra A, Zalenski A, Sannareddy A, Jeune-Smith Y, Kapinos K, Kansagra A. Barriers to chimeric antigen receptor t-cell (CAR-T) therapies in clinical practice. Pharmaceut Med. 2022. https:\/\/doi.org\/10.1007\/s40290-022-00428-w.","journal-title":"Pharmaceut Med."},{"key":"1860_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00432-z","author":"T Lu","year":"2023","unstructured":"Lu T, Zhang J, Xu-Monette ZY, Young KH. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s40164-023-00432-z.","journal-title":"Exp Hematol Oncol"},{"key":"1860_CR25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","author":"H Tilly","year":"2021","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large b-cell lymphoma. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"key":"1860_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00172","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/jco.19.00172.","journal-title":"J Clin Oncol"},{"key":"1860_CR27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794","author":"LH Sehn","year":"2022","unstructured":"Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022. https:\/\/doi.org\/10.1182\/bloodadvances.2021005794.","journal-title":"Blood Adv"},{"key":"1860_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00139-x","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021. https:\/\/doi.org\/10.1016\/s1470-2045(21)00139-x.","journal-title":"Lancet Oncol"},{"key":"1860_CR29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459","author":"PF Caimi","year":"2023","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2023.283459.","journal-title":"Haematologica"},{"key":"1860_CR30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283480","author":"J Duell","year":"2023","unstructured":"Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2023.283480.","journal-title":"Haematologica"},{"key":"1860_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30225-4","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020. https:\/\/doi.org\/10.1016\/s1470-2045(20)30225-4.","journal-title":"Lancet Oncol"},{"key":"1860_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"key":"1860_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00889-8","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021. https:\/\/doi.org\/10.1016\/s0140-6736(21)00889-8.","journal-title":"Lancet"},{"key":"1860_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01725","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 Bispecific T-Cell-engaging antibody, in relapsed or refractory large b-cell lymphoma: dose expansion in a Phase I\/II Trial. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.22.01725.","journal-title":"J Clin Oncol"},{"key":"1860_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(20)30120-4","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020. https:\/\/doi.org\/10.1016\/s2352-3026(20)30120-4.","journal-title":"Lancet Haematol"},{"key":"1860_CR36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157496","author":"M Maerevoet","year":"2022","unstructured":"Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, et al. Selinexor in combination with R-GDP for patients with relapsed\/refractory b-cell lymphoma: final results of 18 patients treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study. Blood. 2022. https:\/\/doi.org\/10.1182\/blood-2022-157496.","journal-title":"Blood"},{"key":"1860_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(18)30177-7","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018. https:\/\/doi.org\/10.1016\/s2352-3026(18)30177-7.","journal-title":"Lancet Haematol"},{"key":"1860_CR38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large b-cell lymphoma. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"key":"1860_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00279-9","author":"S Nagai","year":"2021","unstructured":"Nagai S. Regulatory hurdles for CAR T-cell therapy in Japan. Lancet Haematol. 2021. https:\/\/doi.org\/10.1016\/S2352-3026(21)00279-9.","journal-title":"Lancet Haematol"},{"key":"1860_CR40","unstructured":"YESCARTA\u00ae Package Insert. 2023. https:\/\/www.hsa.gov.sg\/docs\/default-source\/hprg-atpb\/approved-pi-and-pil\/yescarta-pi-approved-01-march-2023.pdf. Last updated on January 2023. Accessed 8 March 2024."},{"key":"1860_CR41","unstructured":"KYMRIAH\u00ae Package Insert. 2019. https:\/\/www.hsa.gov.sg\/docs\/default-source\/hprg-atpb\/approved-pi-and-pil\/kymriah-pi-approved-3-march-20217b6fa01f18d649e68058aa58db1fdf46.pdf. Last updated on July 2019. Accessed 8 March 2024."},{"key":"1860_CR42","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.008","author":"JH Yi","year":"2023","unstructured":"Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, et al. Outcomes in refractory diffuse large b-cell lymphoma: results from two prospective Korean cohorts. Cancer Res Treat. 2023. https:\/\/doi.org\/10.4143\/crt.2022.008.","journal-title":"Cancer Res Treat"},{"key":"1860_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1282323","author":"JY Cho","year":"2024","unstructured":"Cho JY, Jang SC, Kang DW, Lee EK, Koh H, Yoon DH, et al. A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1282323.","journal-title":"Front Oncol"},{"key":"1860_CR44","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023015","author":"JM Byun","year":"2023","unstructured":"Byun JM. Practical issues in CAR T-cell therapy. Blood Res. 2023. https:\/\/doi.org\/10.5045\/br.2023.2023015.","journal-title":"Blood Res"},{"key":"1860_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18335","author":"L Shargian","year":"2022","unstructured":"Shargian L, Raanani P, Yeshurun M, Gafter-Gvili A, Gurion R. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: a systematic review and meta-analysis. Br J Haematol. 2022. https:\/\/doi.org\/10.1111\/bjh.18335.","journal-title":"Br J Haematol"},{"key":"1860_CR46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006280","author":"RT Maziarz","year":"2022","unstructured":"Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, et al. Indirect comparison of tisagenlecleucel and historical treatments for relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2022. https:\/\/doi.org\/10.1182\/bloodadvances.2021006280.","journal-title":"Blood Adv"},{"key":"1860_CR47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003848","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021. https:\/\/doi.org\/10.1182\/bloodadvances.2020003848.","journal-title":"Blood Adv"},{"key":"1860_CR48","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1658","author":"J Kim","year":"2023","unstructured":"Kim J, Cho J, Yoon SE, Kim WS, Kim SJ. Efficacy of salvage treatments in relapsed or refractory diffuse large b-cell lymphoma including chimeric antigen receptor t-cell therapy: a systematic review and meta-analysis. Cancer Res Treat. 2023. https:\/\/doi.org\/10.4143\/crt.2022.1658.","journal-title":"Cancer Res Treat"},{"key":"1860_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3259","author":"W Sang","year":"2020","unstructured":"Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020. https:\/\/doi.org\/10.1002\/cam4.3259.","journal-title":"Cancer Med"},{"key":"1860_CR50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1708566.","journal-title":"N Engl J Med"},{"key":"1860_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110028","author":"H Xu","year":"2023","unstructured":"Xu H, Li N, Wang G, Cao Y. Predictive short\/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed\/refractory B-cell lymphomas. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1110028.","journal-title":"Front Immunol"},{"key":"1860_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103941.","journal-title":"EBioMedicine"},{"key":"1860_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1860_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022. https:\/\/doi.org\/10.1038\/s41571-022-00607-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1860_CR55","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3479","author":"ZY Xu-Monette","year":"2015","unstructured":"Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015. https:\/\/doi.org\/10.18632\/oncotarget.3479.","journal-title":"Oncotarget"},{"key":"1860_CR56","doi-asserted-by":"publisher","DOI":"10.5045\/br.2017.52.3.193","author":"HY Kim","year":"2017","unstructured":"Kim HY, Jang MA, Kim HJ, Kim SJ, Kim WS, Kim SH. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. Blood Res. 2017. https:\/\/doi.org\/10.5045\/br.2017.52.3.193.","journal-title":"Blood Res"},{"key":"1860_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn392","author":"D Ennishi","year":"2008","unstructured":"Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008. https:\/\/doi.org\/10.1093\/annonc\/mdn392.","journal-title":"Ann Oncol"},{"key":"1860_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/03000605221110075","author":"T Yin","year":"2022","unstructured":"Yin T, Qi L, Zhou Y, Kong F, Wang S, Yu M, et al. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China. J Int Med Res. 2022. https:\/\/doi.org\/10.1177\/03000605221110075.","journal-title":"J Int Med Res"},{"key":"1860_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224247","author":"HY Na","year":"2019","unstructured":"Na HY, Choe JY, Shin SA, Kim HJ, Han JH, Kim HK, et al. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: high incidence of BCL2 and MYC double-expressors. PLoS ONE. 2019. https:\/\/doi.org\/10.1371\/journal.pone.0224247.","journal-title":"PLoS ONE"},{"key":"1860_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211053120","author":"A Rampotas","year":"2021","unstructured":"Rampotas A, Sangha G, Collins GP. Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma. Ther Adv Hematol. 2021. https:\/\/doi.org\/10.1177\/20406207211053120.","journal-title":"Ther Adv Hematol"},{"key":"1860_CR61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419","author":"J Kim","year":"2024","unstructured":"Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2023023419.","journal-title":"Blood"},{"key":"1860_CR62","doi-asserted-by":"publisher","DOI":"10.7326\/m22-2276","author":"AH Kelkar","year":"2023","unstructured":"Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, et al. Second-line chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: a cost-effectiveness analysis. Ann Intern Med. 2023. https:\/\/doi.org\/10.7326\/m22-2276.","journal-title":"Ann Intern Med"},{"key":"1860_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1808981","author":"BP Cher","year":"2020","unstructured":"Cher BP, Gan KY, Aziz MIA, Lin L, Hwang WYK, Poon LM, et al. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore\u2019s healthcare system perspective. J Med Econ. 2020. https:\/\/doi.org\/10.1080\/13696998.2020.1808981.","journal-title":"J Med Econ"},{"key":"1860_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1922066","author":"XJ Wang","year":"2021","unstructured":"Wang XJ, Wang YH, Li SCT, Gkitzia C, Lim ST, Koh LP, et al. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore\u2019s private insurance payer\u2019s perspective. J Med Econ. 2021. https:\/\/doi.org\/10.1080\/13696998.2021.1922066.","journal-title":"J Med Econ"},{"key":"1860_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.004","author":"K Thavorn","year":"2024","unstructured":"Thavorn K, Thompson ER, Kumar S, Heiskanen A, Agarwal A, Atkins H, et al. Economic evaluations of chimeric antigen receptor T-cell therapies for hematologic and solid malignancies: a systematic review. Value Health. 2024. https:\/\/doi.org\/10.1016\/j.jval.2024.04.004.","journal-title":"Value Health"},{"key":"1860_CR66","unstructured":"Ministry of Health Cancer Drug List. 2024. https:\/\/www.moh.gov.sg\/home\/our-healthcare-system\/medishield-life\/what-is-medishield-life\/what-medishield-life-benefits\/cancer-drug-list. Last updated on 1 March 2024. Accessed 8 March 2024."},{"key":"1860_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01962-0","author":"F S\u00e1nchez-Guijo","year":"2023","unstructured":"S\u00e1nchez-Guijo F, Avenda\u00f1o-Sol\u00e1 C, Badim\u00f3n L, Bueren JA, Canals JM, Delgadillo J, et al. Role of hospital exemption in Europe: position paper from the Spanish advanced therapy network (TERAV). Bone Marrow Transplant. 2023. https:\/\/doi.org\/10.1038\/s41409-023-01962-0.","journal-title":"Bone Marrow Transplant"},{"key":"1860_CR68","unstructured":"Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. 2024. https:\/\/www.ace-hta.gov.sg\/docs\/default-source\/drug-guidances\/tisagenlecleucel-for-relapsed-or-refractory-dlbcl-after-two-or-more-lines-of-systemic-therapy-(1-aug-24).pdf?sfvrsn=488a3cd7_3. Published 1 August 2024. Accessed 15 Nov 2024."},{"key":"1860_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-020-00628-1","author":"S Lundh","year":"2020","unstructured":"Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, et al. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clin Exp Med. 2020. https:\/\/doi.org\/10.1007\/s10238-020-00628-1.","journal-title":"Clin Exp Med"},{"key":"1860_CR70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146032","author":"R Cusatis","year":"2021","unstructured":"Cusatis R, Tan I, Piehowski C, Akinola I, Crawford E, Craig J, et al. Worsening financial toxicity among patients receiving chimeric antigen receptor t-cell (CAR-T) therapy: a mixed methods longitudinal study. Blood. 2021. https:\/\/doi.org\/10.1182\/blood-2021-146032.","journal-title":"Blood"},{"key":"1860_CR71","unstructured":"Expanded access to cutting edge CAR T-cell therapy. 2020. https:\/\/www.health.gov.au\/ministers\/the-hon-greg-hunt-mp\/media\/expanded-access-to-cutting-edge-car-t-cell-therapy. Published 20 January 2020. Accessed 15 Nov 2024."},{"key":"1860_CR72","unstructured":"Lymphoma patients to benefit from new cancer therapy. 2021. https:\/\/www.health.gov.au\/ministers\/the-hon-greg-hunt-mp\/media\/lymphoma-patients-to-benefit-from-new-cancer-therapy. Published 5 August 2021. Accessed 15 Nov 2024."},{"key":"1860_CR73","doi-asserted-by":"publisher","DOI":"10.31547\/bct-2023-023","author":"WY Hwang","year":"2024","unstructured":"Hwang WY, Takahashi S, Choi B, Huang H, Kawamata S, Ng SC, et al. Challenges in global access to CAR-T cells: an Asian perspective. Blood Cell Ther. 2024. https:\/\/doi.org\/10.31547\/bct-2023-023.","journal-title":"Blood Cell Ther"},{"key":"1860_CR74","unstructured":"Speech by Minister for Health Mr Ong Ye Kung at the Singapore Cell and Gene Therapy Conference and Launch of the Advanced Cell Therapy and Research Institute (Actris), on 4 August 2023. 2023. https:\/\/www.moh.gov.sg\/newsroom\/speech-by-minister-for-health-mr-ong-ye-kung-at-the-singapore-cell-and-gene-therapy-conference-and-launch-of-the-advanced-cell-therapy-and-research-institute-(actris)-on-4-august-2023. Published 4 August 2023. Accessed 15 Nov 2024."},{"key":"1860_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3065","author":"FL Wei Inng Lim","year":"2022","unstructured":"Wei Inng Lim FL, Yunxin C, Huang FJ, Khee Hwang WY. A unique hub-and-spoke model to optimize patient management in lymphoma using novel CAR-T cell therapy in Southeast and South Asia. Hematol Oncol. 2022. https:\/\/doi.org\/10.1002\/hon.3065.","journal-title":"Hematol Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01860-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:17Z","timestamp":1739491217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01860-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1860"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01860-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u2022Ya Hwee Tan: Travel support from Gilead. \u2022Dok Hyun Yoon: Honoraria from Roche, Janssen, Amgen, BMS, Kirin, Boryung and Takeda; Consulting\/advisory role at Roche, Janssen, Amgen, BMS, Novartis, Abclone, GI cell, GC cell and Pharos Bio; Research funding from Samyang, Kirin, Roche, Janssen, Boryung. \u2022Andrew J Davies: Research funding and support from Celgene, Roche, Kite, GSK, Janssen, Karyopharm Therapeutics, Acerta Pharma\/AstraZeneca, and ADC Therapeutics; Advisory board role at Celgene, Roche, Kite, Genmab, Karyopharm Therapeutics, Sobi, Incyte, and AbbVie; Honorarium from Celgene, Roche, Kite, Genmab, Janssen, Acerta Pharma\/AstraZeneca, and ADC Therapeutics; Travel support from Celgene and Roche. \u2022Christian Buske: Honoraria from Roche\/Genentech, Janssen, BeiGene, Novartis, Pfizer, Incyte, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron, Sobi, Lilly; Consulting or advisory role at Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Incyte, Regeneron, MorphoSys, Novartis, Sobi, Lilly; Speakers\u2019 bureau for Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences, Novartis, Gilead, Incyte, Pfizer, MorphoSys, Sobi, Lilly; Research funding from Roche\/Genentech, Janssen, Celltrion, MSD, Pfizer, Amgen, Bayer. \u2022Yang Liang Boo: Nothing to disclose. \u2022Nagavalli Somasundaram: Nothing to disclose. \u2022Francesca Lim: Nothing to disclose. \u2022Shin Yeu Ong: Nothing to disclose. \u2022Anand Jeyasekharan: Consultancy fees from DKSH\/Beigene, Roche, Gilead, Turbine Ltd, AstraZeneca, Antengene, Janssen, MSD and IQVIA; Research funding from Janssen and AstraZeneca. \u2022Koji Izutsu: Consulting fees from AstraZeneca, Ono Pharmaceutical, Mitsubishi Tanabe, Eisai, Chugai, Bristol Myers Squibb, AbbVie, Takeda, Zenyaku, Genmab, Kyowa Kirin, MSD, Carna Biosciences, Novartis, Yakult, Nihon Shinyaku, Novartis, Beigene; Honoraria from AstraZeneca, Ono Pharmaceutical, Eisai, Chugai, Janssen, Symbio, Bristol Myers Squibb, Daiichi Sankyo, Otsuka, AbbVie, Takeda, Eli Lilly, Genmab, Kyowa Kirin, MSD, Astellas, Pfizer, Meiji Seika Pharma, Novartis, Nihon Kayaku, Gilead; Research funding from Chugai, Bristol Myers Squibb, Incyte, Genmab, LOXO Oncology, Daiichi Sankyo, BeiGene, AbbVie, AstraZeneca, Regeneron, Yakult, Otsuka, Novartis, Pfizer, MSD, Bayer, Kyowa Kirin, Eisai, Janssen, Ono Pharmaceutical, Gilead, Astellas Amgen. \u2022Won Seog Kim: Grant\/research support from Sanofi, BeiGene, Boryong, Roche, Kyowa Kirin, Donga. \u2022Jason Yongsheng Chan: Consultation\/Speaker\u2019s Bureau: Antengene, Takeda, AstraZeneca, Novartis, Roche, MSD, Specialised Therapeutics, DKSH\/Beigene, Janssen, AbbVie; Grant\/Research support: SymBio Pharmaceuticals, Scinnohub Pharmaceuticals, ArcherDX\/Invitae, Miltenyi Biotec, STEMCELL Technologies, MGI Technologies, BGI Research, Twist Biosciences, Agilent Technologies, Illumina, BioSyngen, NovogeneAIT, Phillips; Travel support: AstraZeneca, Janssen, Amgen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}